Noora (vaccine)

Noora (vaccine)
Vaccine description
Vaccine typeProtein subunit
Clinical data
Routes of

Noora (Persian: نورا) is a COVID-19 vaccine candidate developed by Baqiyatallah University of Medical Sciences in Iran.[1][2]

Medical uses

It requiring three doses given by intramuscular injection on days 0, 21 and 35.[3]


Noora is a recombinant RBD protein subunit vaccine.[3]


Up to 8 December 2021, 5 millions doses have been produced.[4]

Clinical trials

Clinical trials of Noora
PhaseRegistration numberStartNumber of participantsAge of participantsRef
IIRCT20210620051639N125 June 20217030 (80 µg)

30 (120 µg)

10 (placebo)18–50 years[3]
IIIRCT20210620051639N210 October 20213002406018–40 years[5]
IIIIRCT20210620051639N323 December 202110000>18 years[6]

See also


  1. ^ "IRGC starts clinical trial of "Noora" coronavirus vaccine". Tehran Times. 27 June 2021. Retrieved 1 July 2021.
  2. ^ "IRGC Commander: Iran-Made 'Noora' Coronavirus Vaccine Ready for 2nd Stage of Human Trial". Fars News Agency. 22 August 2021. Retrieved 30 August 2021.
  3. ^ a b c "A randomized, double-blinded, placebo-controlled phase I clinical trial to evaluate the safety and immunogenicity of three dose regimens of COVID-19 RBD protein recombinant vaccine (AmitisGen; 80µg and 120µg) in a healthy population". Iranian Clinical Trials Registry. 25 June 2021. IRCT20210620051639N1. Retrieved 1 July 2021.
  4. ^ "5 میلیون دوز واکسن "نورا" تولید شد- اخبار پزشکی - اخبار اجتماعی تسنیم | Tasnim". خبرگزاری تسنیم | Tasnim (in Persian). Retrieved 8 December 2021.
  5. ^ "IRCT | A double-blind, randomized, placebo-controlled Phase II clinical trial to evaluate the immunogenicity and safety of covid-19 recombinant RBD protein vaccine (80 microgram) of Plasma Darman Sarve Sepid Co. in healthy population". Retrieved 27 November 2021.
  6. ^ "IRCT |Phase 3 Clinical Trial to evaluate the Immunogenicity and Safety of Covid19 Recombinant RBD Protein Vaccine (Noora Vaccine) as a Booster Vaccine after injection of existing Vaccines in IRAN". Retrieved 23 December 2021.

Media files used on this page

Coronavirus. SARS-CoV-2.png
Author/Creator: Alexey Solodovnikov (Idea, Producer, CG, Editor), Valeria Arkhipova (Scientific Сonsultant), Licence: CC BY-SA 4.0
Scientifically accurate atomic model of the external structure of the Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2), a strain (genetic variant) of the coronavirus that caused coronavirus disease (COVID-19), first identified in Wuhan, China, during December 2019

Each separate locus (amorphous blob) is an atom of:

cobalt: membrane
crimson: E protein
green: M protein
orange: glucose (glycan)
turquoise : S (spike) glycoprotein
SARS-CoV-2 (Wikimedia colors).svg
Author/Creator: Geraki, Licence: CC BY-SA 4.0
SARS-CoV-2 logo in Wikimedia colors
Scholia logo.svg
Author/Creator: Lars Willighagen, Licence: CC BY-SA 4.0
SVG remake of proposal for Scholia logo (File:Scholia logo.png by User:Theklan).
WHO Rod.svg
The rod of Asclepius as depicted in the WHO logo.
Author/Creator: User:FoeNyx © 2004 (artistic illustration), Licence: CC-BY-SA-3.0
VIH - HIV / SIDA - AIDS viruses.
SARS-CoV-2 (CDC-23312).png
This illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by the 2019 Novel Coronavirus (2019-nCoV). Note the spikes that adorn the outer surface of the virus, which impart the look of a corona surrounding the virion, when viewed electron microscopically. This virus was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China.
Syringe with Green Fluid.jpg
Author/Creator: Andres Rueda, Licence: CC BY 2.0
The following is the author's description of the photograph quoted directly from the photograph's Flickr page.
"Just wanted to test something with my ink refiller syringe. Filled with a oral-b mouthwash to give the greenish-blueish Max Payne valkyr effect. "